Antibiotic use and the risk of flare of inflammatory bowel disease

被引:33
作者
Aberra, FN
Brensinger, CM
Bilker, WB
Lichtenstein, GR
Lewis, JD
机构
[1] Univ Penn, Sch Med, Div Gastroenterol, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
[3] Vet Affairs Med Ctr, Philadelphia, PA USA
关键词
D O I
10.1016/S1542-3565(05)00020-0
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Intestinal microbial flora participate in the pathogenesis of inflammatory bowel disease. Because antibiotic therapy alters intestinal microbial flora, we hypothesized that use of antibiotics might decrease the risk of flare. Methods: We conducted a case-crossover study by using the General Practice Research Database from 1989-1997. Flares of disease were identified by receipt of a new prescription for either corticosteroids or mesalamine medications after an interval of at least 4 months without prescriptions for either class of medication. The primary exposure was receipt of any antibiotics in the 60 days preceding the index date. Results: Among 1205 patients with Crohn's disease, exposure to antibiotics was associated with a reduced risk of flare (adjusted odds ratio [OR], 0.78; 95% confidence interval [CI], 0.64-0.96; P =.019). The effect was strongest with more recent exposure (test for trend, P <.05). Among 2230 patients with ulcerative colitis, use of any antibiotics within 60 days was not associated with flare of disease (adjusted OR, 0.96; 95% Cl, 0.82-1.12; P =.581), although a potentially protective effect was observed in those patients with very recent exposure (exposure within 15 days: OR, 0.66; 95% Cl, 0.51-0.85). Conclusions: Antibiotic use within 60 days was associated with a lower risk of flare of Crohn's disease, but not ulcerative colitis. The strength of the protective effect of antibiotics in Crohn's disease wanes over time.
引用
收藏
页码:459 / 465
页数:7
相关论文
共 36 条
[1]   METRONIDAZOLE INHIBITS LEUKOCYTE-ENDOTHELIAL CELL-ADHESION IN RAT MESENTERIC VENULES [J].
ARNDT, H ;
PALITZSCH, KD ;
GRISHAM, MB ;
GRANGER, DN .
GASTROENTEROLOGY, 1994, 106 (05) :1271-1276
[2]   Preliminary study of ciprofloxacin in active Crohn's disease [J].
Arnold, GL ;
Beaves, MR ;
Pryjdun, VO ;
Mook, WJ .
INFLAMMATORY BOWEL DISEASES, 2002, 8 (01) :10-15
[3]   Down-regulation of intestinal lymphocyte activation and Th1 cytokine production by antibiotic therapy in a murine model of Crohn's disease [J].
Bamias, G ;
Marini, M ;
Moskaluk, CA ;
Odashima, M ;
Ross, WG ;
Rivera-Nieves, J ;
Cominelli, F .
JOURNAL OF IMMUNOLOGY, 2002, 169 (09) :5308-5314
[4]  
BURKE DA, 1990, ALIMENT PHARM THERAP, V4, P123
[5]   Mortality in inflammatory bowel disease: A population-based cohort study [J].
Card, T ;
Hubbard, R ;
Logan, RFA .
GASTROENTEROLOGY, 2003, 125 (06) :1583-1590
[6]  
Casellas F, 1998, INFLAMM BOWEL DIS, V4, P1
[7]   A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease [J].
Colombel, JF ;
Lémann, M ;
Cassagnou, M ;
Bouhnik, Y ;
Duclos, B ;
Dupas, JL ;
Notteghem, B ;
Mary, JY .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 1999, 94 (03) :674-678
[8]   Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum [J].
D'Haens, GR ;
Geboes, K ;
Peeters, M ;
Baert, F ;
Pennickx, F ;
Rutgeerts, P .
GASTROENTEROLOGY, 1998, 114 (02) :262-267
[9]  
Dianda L, 1997, AM J PATHOL, V150, P91
[10]   Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis [J].
Gionchetti, P ;
Rizzello, F ;
Venturi, A ;
Ugolini, F ;
Rossi, M ;
Brigidi, P ;
Johansson, R ;
Ferrieri, A ;
Poggioli, G ;
Campieri, M .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1999, 13 (06) :713-718